FDA Postpones Meeting , With Expert Advisers , on Pfizer's Vaccine for Young Kids.<br />FDA Postpones Meeting , With Expert Advisers , on Pfizer's Vaccine for Young Kids.<br />NPR reports that the FDA has postponed <br />a meeting of expert advisers about the use of the <br />Pfizer-BioNTech COVID-19 vaccine for young children.<br />NPR reports that the FDA has postponed <br />a meeting of expert advisers about the use of the <br />Pfizer-BioNTech COVID-19 vaccine for young children.<br />Pfizer reportedly told the Food and Drug Administration <br />(FDA) that new data regarding the vaccine's use in <br />children from 6 months to 4 years of age has emerged. .<br />Pfizer reportedly told the Food and Drug Administration <br />(FDA) that new data regarding the vaccine's use in <br />children from 6 months to 4 years of age has emerged. .<br />According to the FDA, the agency postponed <br />the meeting to evaluate the additional data. .<br />We believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization, Food and Drug Administration statement, via NPR.<br />Pfizer and BioNTech were applying <br />for authorization of the first two shots, while <br />data was still being collected on a third dose. .<br />Pfizer and BioNTech were applying <br />for authorization of the first two shots, while <br />data was still being collected on a third dose. .<br />NPR reports that the companies have now<br />changed course, a decision that will delay access <br />to a COVID vaccine for the youngest children. .<br />Given that the study is advancing <br />at a rapid pace, the companies will wait for <br />the three-dose data as Pfizer and BioNTech <br />continue to believe it may provide a higher <br />level of protection in this age group, Pfizer-BioNTech statement, via NPR.<br />The companies expect <br />to have three-dose protection <br />data available in early April, Pfizer-BioNTech statement, via NPR.<br />On February 11, Peter Marks, director <br />of the FDA's Center for Biologics <br />Evaluation and Research, said that, "it makes sense to wait to evaluate <br />a third dose before taking action." .<br />On February 11, Peter Marks, director <br />of the FDA's Center for Biologics <br />Evaluation and Research, said that, "it makes sense to wait to evaluate <br />a third dose before taking action." .<br />We realize the need for a vaccine <br />for COVID-19 — even with the drop <br />in cases. We will do our part to <br />move ahead as fast as we can, Peter Marks, Director of the FDA's Center for <br />Biologics Evaluation and Research, via NPR
